Suven Life Sciences Limited (BOM:530239)
India · Delayed Price · Currency is INR 308.50
-11.50 (-3.59%)
At close: Oct 1, 2026
Suven Life Sciences Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 87,171 | 35,035 | 24,730 | 21,742 | 10,570 | 13,484 | |
Market Cap Growth | 88.45% | 41.67% | 13.74% | 105.69% | -21.61% | 50.48% |
Enterprise Value | 82,156 | 32,460 | 23,067 | 19,870 | 10,468 | 13,313 |
Last Close Price | 308.50 | 132.85 | 113.40 | 99.70 | 48.47 | 85.47 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Forward PE | - | 3.65 | 3.65 | 3.65 | 3.65 | 3.65 |
PS Ratio | 989.02 | 492.44 | 371.55 | 185.94 | 77.75 | 112.83 |
PB Ratio | 14.74 | 5.92 | 22.48 | 8.05 | 2.82 | 14.03 |
P/TBV Ratio | 14.74 | 5.93 | 22.52 | 8.06 | 2.82 | 14.06 |
PEG Ratio | - | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | - | 456.24 | 346.57 | 169.93 | 77.00 | 111.40 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.03 | 0.03 | - | 0.00 | 0.00 | 0.03 |
Net Debt / Equity Ratio | -0.85 | -0.85 | -0.55 | -0.89 | -0.60 | -0.49 |
Net Debt / EBITDA Ratio | 1.37 | 1.76 | 0.36 | 1.86 | 1.80 | 0.39 |
Net Debt / FCF Ratio | - | 1.64 | 0.31 | 2.07 | 1.91 | 0.32 |
Asset Turnover | - | 0.02 | 0.03 | 0.04 | 0.06 | 0.10 |
Inventory Turnover | - | 0.23 | 1.59 | 2.30 | 27.66 | 9.10 |
Quick Ratio | - | 28.01 | 2.67 | 18.01 | 21.03 | 7.13 |
Current Ratio | - | 29.16 | 3.21 | 18.99 | 22.61 | 8.01 |
Return on Equity (ROE) | - | -78.80% | -84.60% | -32.56% | -50.17% | -119.51% |
Return on Assets (ROA) | - | -47.69% | -50.94% | -24.91% | -33.21% | -66.72% |
Return on Invested Capital (ROIC) | -413.71% | -414.00% | -423.40% | -149.73% | -133.77% | -218.87% |
Return on Capital Employed (ROCE) | - | -47.90% | -153.30% | -49.50% | -35.00% | -126.60% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | -4.04% | -7.89% | -6.50% | -4.83% | -11.19% | -9.05% |
FCF Yield | -3.52% | -8.75% | -7.74% | -5.31% | -11.25% | -10.93% |
Dividend Yield | - | - | - | - | - | 1.17% |
Buyback Yield / Dilution | -9.53% | -4.44% | - | -22.31% | -32.29% | -5.88% |
Total Shareholder Return | -9.53% | -4.44% | - | -22.31% | -32.29% | -4.71% |